CRISPR Therapeutics AG (CRSP) closed at $55.16, down 2.56% from the previous day. The stock underperformed the S&P 500, which saw a 0.13% increase. In the past month, CRSP shares dropped by 24.44%. The upcoming earnings report projects an EPS of -$1.32 and revenue of $6.71 million, marking significant changes from the previous year.

Analysts have made revisions to estimates for CRISPR Therapeutics AG, indicating changing business trends. The Zacks Rank system, ranging from #1 to #5, currently rates CRSP as a #3 (Hold). The Medical – Biomedical and Genetics industry, to which CRSP belongs, has a Zacks Industry Rank of 90, placing it in the top 37% of industries.

Research Chief Sheraz Mian names a top stock pick expected to double in value. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter. The pullback in stock price presents a potential opportunity for investors. Access more Zacks top stock picks for free.

Read more at Nasdaq: CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note